An L-threonine aldolase mutant and a method for producing L-serine.

By employing a strategy of amino acid sequence mutation of L-threonine aldolase and batch-adding formaldehyde, the yield and cost issues in L-serine production were resolved, achieving efficient and economical L-serine synthesis.

CN123107978APending Publication Date: 2026-11-17TIANJIN INST OF IND BIOTECH CHINESE ACADEMY OF SCI +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611534132.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-30
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing methods for producing L-serine have problems such as insufficient output to meet market demand, difficulties in subsequent separation, high purification costs, and high requirements for production equipment. In particular, coenzyme tetrahydrofolic acid is unstable and expensive in enzymatic production.

Method used

To develop an L-threonine aldolase mutant by replacing amino acids at positions 248 or 290 of the wild-type L-threonine aldolase with lysine or isoleucine, an L-threonine aldolase mutant was formed for efficient catalysis of the synthesis of L-serine from glycine and formaldehyde without the need for tetrahydrofolate, and a strategy of adding formaldehyde in batches was adopted to protect enzyme activity.

Benefits of technology

Without the need for the addition of tetrahydrofolate, the conversion rate and yield of L-serine were significantly improved, with the conversion rate before and after mutation increasing from 28% to 76%, reducing production costs and simplifying the operation process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123107978A_ABST
    Figure CN123107978A_ABST
Patent Text Reader

Abstract

This invention discloses a method for the efficient catalytic production of L-serine using an L-threonine aldolase mutant. The mutant is obtained by a single-point mutation at amino acid position 248 or 290 of the wild-type L-threonine aldolase shown in SEQ ID No. 2. Using formaldehyde and glycine as substrates, this invention employs a more efficient L-threonine aldolase, eliminating the need for expensive or unstable cofactors such as tetrahydrofolate, and combining an optimized formaldehyde addition strategy to achieve highly efficient whole-cell catalytic production of L-serine. This method significantly increases the conversion rate of L-serine from 28% to 76%, demonstrating promising application prospects in the industrial production of L-serine.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of bioengineering technology, specifically relating to an L-threonine aldolase mutant and a method for producing L-serine. Background Technology

[0002] L-serine, also known as L-2-amino-3-hydroxypropionic acid, is a natural non-essential amino acid. However, the human body cannot synthesize enough L-serine to meet all cellular needs, requiring adequate supplementation through diet. Its relative molecular mass is 105.09, and its chemical formula is C3H7NO3. It is a crucial substance involved in various metabolic pathways within the body, playing a vital role in the biosynthesis of proteins, purines, and pyrimidines, as well as the generation of one-carbon units. Furthermore, L-serine has important applications in medicine, food, and cosmetics. In recent years, the application of L-serine in metabolic regulation, cellular antioxidation, and neuroprotection has become a research hotspot. For example, the significant neuroprotective effect of L-serine has demonstrated therapeutic efficacy and good safety in various neurodegenerative diseases such as Alzheimer's and Parkinson's. As a natural moisturizing factor, L-serine can enhance the activity of skin surface cells, maintain the moisture of the stratum corneum, and delay cell aging, thus making it a key additive in skincare products.

[0003] Current methods for preparing L-serine mainly include chemical synthesis, protein hydrolysis, microbial fermentation, and enzymatic catalysis. The main drawbacks of chemical synthesis and protein hydrolysis are their complex reaction steps, requiring multiple purification steps to obtain optically pure chiral L-serine. These methods also suffer from high production costs, low conversion efficiency, and severe environmental pollution, leading to their gradual phasing out. Currently, the primary method for L-serine production is precursor fermentation, using *E. coli* and *Corynebacterium glutamicum* as the chassis cells. However, this method is difficult to separate later, resulting in high costs and demanding equipment. Furthermore, the highest reported yield of L-serine from *E. coli* fermentation to date is only 50... Key indicators such as g / L, yield, and productivity still fall short of the requirements for industrial production. However, enzymatic methods offer advantages such as mild reaction conditions, high specificity, strong stereoselectivity, high product yield, and environmental friendliness. Compared to fermentation, enzymatic methods are simpler and more efficient, with higher production efficiency, fewer side reactions and byproducts, and easier downstream separation and purification. Compared to chemical methods, enzymatic catalysis is characterized by milder conditions, safer operation, simpler equipment, and is more environmentally friendly. It has been widely used in the industrial production of chiral chemicals such as pharmaceutical intermediates and fine chemicals. Currently, the enzyme involved in L-serine biosynthesis is mainly serine hydroxymethyltransferase (SHMT), whose catalytic process is relatively complex. It requires not only PLP as a coenzyme but also tetrahydrofolate as a cofactor. However, tetrahydrofolate is extremely unstable and expensive, leading to increased production costs. Therefore, a relatively simple yet efficient method for producing L-serine is still needed.

[0004] L-threonine aldolases are ubiquitous in nature, found in bacteria, fungi, and mammalian species. Currently, approximately 5,000 sequences annotated as L-TA can be found in databases such as NCBI and Swiss-Prot. However, only a few genes have undergone structural, mechanical, and biochemical studies. L-TA uses pyridoxal-5'-phosphate (PLP) as a cofactor, covalently binding to the Apo-enzyme via a lysine residue at its active site to form a Schiff base intermediate. After the substrate glycine enters the active site, the active lysine residue dissociates from PLP, forming a new Schiff base intermediate with glycine. Then, the α-carbon of glycine is deprotonated, and the nucleophilic acceptor formaldehyde, entering the active site, forms a new C-C bond with the α-carbon. Finally, PLP recombines with the active lysine residue to form the Schiff base intermediate, releasing the product L-serine.

[0005] To date, the enzyme with the highest yield in the enzymatic production of L-serine is serine hydroxymethyltransferase, but its reaction process is complex, and it is mostly used in fermentation to produce L-serine. In addition, other reported enzymatic cascade reactions for L-serine production involve multiple enzymes, which are also complex and have lower yields.

[0006] Therefore, the discovery of a highly active L-threonine aldolase that can efficiently catalyze the synthesis of L-serine from glycine and formaldehyde without the need for tetrahydrofolate has significant application potential in industrial production. Summary of the Invention

[0007] The purpose of this invention is to provide an L-threonine aldolase mutant and a method for producing L-serine. The L-threonine aldolase mutant can efficiently catalyze the synthesis of L-serine from glycine and formaldehyde without the addition of tetrahydrofolate, solving the problem that the current L-serine production cannot fully meet market demand. Currently, the main production method is fermentation, which has drawbacks such as difficulty in subsequent separation, high purification costs, and high requirements for production equipment.

[0008] To achieve the above objectives, the present invention adopts the following technical solution: A mutant of L-threonine aldolase, wherein the L-threonine aldolase mutant is obtained by a single mutation of amino acid position 248 or 290 of the amino acid sequence of the wild-type L-threonine aldolase shown in SEQ ID No. 2.

[0009] MNGETSRPPALGFSSDNIAGASPEVAQALVKHSSGQAGPYGTDELTAQVKRKFCEIFERDVEVFLVPTGTAANALCLSAMTPPWGNIYCHPASHINNDECGAPEFFSNGAKLMTVDGPAAKLDIVRLRERTREKVGDVHTTQPACVSITQATEVGSIYTLDEIEAIGDVCKSSSSLGLHMD GSRFANALVSLGCSPAEMTWKAGVDALSFGATKNGVLAAEAIVLFNTSLATEMSYRRKRAGHLSSKMRFLSAQIDAYLTDDLWLRNARKANAAAQRLAQGLEGLGGVEVLGGTEANILFCRLDSAMIDALLKAGFGFYHDRWGPNVVRFVTSFATTAEDVDHLLNQVRLAADRTQER (SEQ ID No.2).

[0010] The L-threonine aldolase mutant is obtained by replacing serine at position 248 or 290 of the amino acid sequence shown in SEQ ID No. 2 with lysine or isoleucine.

[0011] The gene encoding the L-threonine aldolase mutant as described in claim 1.

[0012] The recombinant expression vector expressing the L-threonine aldolase mutant encoding gene as described in claim 3.

[0013] A method for the efficient catalytic production of L-serine using an L-threonine aldolase mutant is disclosed. The method utilizes wet bacterial cells obtained through fermentation of a recombinant expression transformant of the L-threonine aldolase mutant, or crude enzyme solution obtained by ultrasonic disruption of wet bacterial cells, as a catalyst. Formaldehyde and glycine are used as substrates, and pyridoxal phosphate and magnesium sulfate heptahydrate are added. A buffer solution with pH 6-10 is used as the reaction medium to form the reaction system. The reaction is carried out at 30-50℃ and 200-300 rpm to obtain a reaction solution containing L-serine.

[0014] The amount of catalyst added in the reaction system is 10-80 g / L based on the weight of wet bacterial cells or wet bacterial cells before ultrasonic disruption; the final concentration of formaldehyde is 0.1-1 M; the final concentration of glycine is 10-100 g / L; the final concentration of pyridoxal phosphate is 10-200 mg / L; and the final concentration of magnesium sulfate heptahydrate is 8-19 g / L.

[0015] The catalyst addition amount in the reaction system is preferably 50 g / L based on the weight of wet bacterial cells or wet bacterial cells before ultrasonic disruption; the final concentration of formaldehyde addition is preferably 1 M; the final concentration of glycine addition is preferably 75 g / L; and the final concentration of magnesium sulfate heptahydrate addition is preferably 5-15 g / L.

[0016] The buffer solution is a 0.2M, pH 7.5 potassium phosphate buffer.

[0017] The catalyst was prepared as follows: The recombinant expression transformant of the L-threonine aldolase mutant was inoculated into a test tube containing LB liquid medium with 50 μg / mL kanamycin and cultured overnight at 37°C and 220 rpm in a shaker. The bacterial culture was inoculated at a volume concentration of 1% into TB liquid medium containing 50 μg / L kanamycin and cultured at 37°C and 220 rpm in a shaker until the OD600 reached 0.6-0.8. 0.1 mM IPTG was added to a final concentration, and expression was induced for 12-14 h at 25°C and 220 rpm in a shaker. The culture was then centrifuged at 4°C and 4000 rpm for 10 min to obtain wet cells. The wet cells were resuspended in 50 mM PBS buffer (pH 7.4) and washed. The supernatant was discarded after centrifugation at 4000 rpm for 10 min to obtain wet cells. The wet cells were then added at a concentration of 50 g / L to 50 mM PBS buffer (pH 7.4). Resuspend the enzyme in 0.4% PBS buffer, sonicate at 300W for 10 min, working for 2 seconds and then 3 seconds, centrifuge at 4000 rpm for 15 min at 4℃, collect the supernatant to obtain crude enzyme solution.

[0018] Formaldehyde was added in batches, gradually. Specifically, during the reaction, a formaldehyde solution with a concentration ranging from 10 to 300 millimoles per liter (mM) was added to the reaction system in portions at set time intervals (usually 20 to 60 minutes). This non-single, gradual addition method, compared to adding a large amount of formaldehyde at once, significantly slowed down the instantaneous increase in formaldehyde concentration in the system, thus effectively avoiding the severe impact of high-concentration formaldehyde on enzyme molecules. Because formaldehyde has strong reactivity and potential toxicity, if an excessive amount is added at once, it is very easy to cause irreversible reactions with key functional groups such as amino and thiol groups in the enzyme protein, leading to damage to the enzyme structure and conformational changes, thereby significantly inhibiting its catalytic activity. However, by adding formaldehyde in stages, in small doses, and at regular intervals, not only can the formaldehyde concentration in the reaction system be maintained at a relatively mild and controllable level, but the toxic effects of formaldehyde on enzyme molecules can also be minimized while meeting the reaction requirements, thereby effectively mitigating its inhibitory effect on enzyme activity and ensuring the stability and catalytic efficiency of the enzyme during the reaction process.

[0019] The present invention proposes an L-threonine aldolase mutant and a method for producing L-serine. The beneficial effects of the above technical solution are mainly reflected in the following: without the need to add expensive coenzyme tetrahydrofolate, L-serine can be prepared by efficiently catalyzing the aldol condensation reaction of formaldehyde and glycine. The conversion rate of L-serine is increased from 28% before mutation to 76%, and the yield is significantly improved, showing good application prospects in the synthesis of L-serine. Attached Figure Description

[0020] Figure 1 This is a schematic diagram of the interaction pattern between WT and the L-serine-PLP complex in Example 1.

[0021] Figure 2 The image shows SDS-PAGE images of whole cells, supernatant, and precipitate after WT, R248K, and L290I induction culture in Example 3. Lane M represents the DNA marker, lanes 1, 2, and 3 represent whole cells, supernatant, and precipitate of WT, lanes 4, 5, and 6 represent whole cells, supernatant, and precipitate of R248K, and lanes 6, 7, and 8 represent whole cells, supernatant, and precipitate of L290I.

[0022] Figure 3 The reaction formula is for the production of L-serine from formaldehyde and glycine catalyzed by L-threonine aldolase.

[0023] Figure 4 A bar chart showing the yield of L-serine synthesized from formaldehyde and glycine by L-threonine aldolase and its mutant. Detailed Implementation

[0024] The present invention will be further described below with reference to specific embodiments, but the scope of protection of the present invention is not limited thereto: Materials and reagents used in the embodiments of this invention: E. coli BL21(DE3) and plasmid pET-24a(+) are commercially available; plasmid extraction kit and DNA purification and recovery kit were purchased from TIANGEN Biochemical Technology (Beijing) Co., Ltd.; SDS-PAGE precast gels were purchased from Nanjing Genscript Biotech Co., Ltd.; DNA marker Good and View nucleic acid dyes were purchased from Beijing Qingke Biotechnology Co., Ltd.; the usage of the above reagents should be in accordance with the product instructions.

[0025] Primer synthesis and sequence sequencing were performed by Tianjin Youkang Biotechnology Co., Ltd.

[0026] Glycine was purchased from Shanghai Titan Technology, and the rest were purchased from Sinopharm Chemical Reagent Co., Ltd.

[0027] Example 1: Construction of the starting strain The sequence labeled as phenylserine aldolase from *Pseudomonas putida* (NCBI accession number BAD91544.1) was cloned and designated as the L-threonine aldolase Pp-LTA ​​fragment (gene sequence shown in SEQ ID No. 1, amino acid sequence shown in SEQ ID No. 2). This fragment was inserted between the NdeI and XhoI restriction sites of the expression plasmid pET-24a(+) to obtain pET24a- Pp - LTA. After sequencing verification confirms no errors, pET24a- Pp -LTA is transferred into the expression host E. coli E. coli BL21(DE3) yielded the starting strain. E. coli BL21(DE3)-pET24a- Pp -LTA (strain abbreviation WT), the corresponding protein is denoted as wild type Pp-LTA.

[0028]

[0029] Example 2: Construction and Screening of Mutants 1) Selection of mutation sites Download the wild-type Pp-LTA ​​protein structure from the NCBI database and convert it to wild-type using AutoDock software. Pp -LTA was molecularly docked with the L-serine-PLP complex (e.g. Figure 1 (As shown); Analysis revealed that amino acid residues within a 5 Å van der Waals distance around the L-serine-PLP complex may be involved in formaldehyde molecule binding and enzyme activity regulation. Therefore, these residues were selected as candidate mutation sites, specifically including 16 sites: D16, E58, D98, K121, V125, T149, T152, V154, E162, S182, R248, L290, F299, R237, Y318, and W322.

[0030] 2) Construction of site-directed saturation mutant libraries Extraction of plasmid pET24a- from Example 1 Pp Using -LTA as a template, saturation mutation primers were designed for the 10 selected mutation sites (Table 1), and KOD One was used. TM The Mega-PCR method of PCR Master MIX (TAKARA) is used to construct mutant libraries for screening.

[0031] PCR system: The reaction volume is 20 µL, including 8 µL of water and 10 µL of KOD One. TM PCR Master MIX, 0.5 µL forward primer (10 µM), 0.5 µL reverse primer (10 µM), and 1 µL template DNA (5–10 ng / µL).

[0032] Short fragment PCR program: pre-denaturation at 98 °C for 2 minutes, followed by 30 cycles (98 °C for 10 seconds, 60 °C for 15 seconds, 72 °C for 4 seconds), and a final extension at 72 °C for 3 minutes, followed by storage at 16 °C; the PCR products from one round were gel-cleaved and recovered, and the recovered products were used as primers for Mega-PCR.

[0033] Mega-PCR program: pre-denaturation at 98 °C for 2 minutes, followed by 30 cycles (98 °C for 10 seconds, 60 °C for 15 seconds, 72 °C for 45 seconds), and a final extension at 72 °C for 3 minutes, then storage at 16 °C.

[0034] Table 1 Primers used for mutant construction. .

[0035] In Table 1, N represents bases A / C / G / T, M represents bases A / C, and K represents bases G / T.

[0036] 3) Screening for mutants: (1) Preparation of wet cells of genetically engineered bacteria expressing mutants The PCR products were verified by 1% agarose gel electrophoresis. Successfully verified PCR products were then digested with DpnI enzyme at 37°C for at least 2 hours. Transfection into *E. coli* host: After digestion, 2 µL of the digested product was directly electroporated to… E. coli In BL21(DE3) competent cells, after incubation at 37 °C with shaking for 1 hour, the bacterial culture was spread onto LB agar plates and incubated at 37 °C for 12 hours. The next day, single colonies were selected and inoculated into 5 mL of LB liquid medium, and sequenced after incubation. Simultaneously, plates with good colony condition and sufficient quantity were selected for scraping and sequencing. PCR products with satisfactory sequencing results were subjected to secondary electroporation, incubated, and then plated, incubated at 37 °C for 12-14 hours. The next day, single colonies were selected and inoculated into 96-well plates, with 300 μL of LB medium containing Amp added to each well. The plates were incubated at 37 °C with shaking (800 rpm) for 8-10 hours. 60 μL of 60% glycerol was added to a 96-well glycerol preservation plate beforehand, and 120 μL of the cultured bacterial culture was transferred to the glycerol preservation plate and stored at -80 °C for future use. Next, 800 μL of TB medium containing 0.2 mM IPTG and 50 μg / mL kanamycin was added, and expression was induced at 28°C and 800 rpm for 12-14 hours. After culture, the cells were collected by centrifugation at 4°C and 4000 rpm for 10 minutes, washed with 400 μL of PB buffer (50 mM, pH 7.4), and then centrifuged at 4°C and 4000 rpm for 10 minutes to collect the wet cells.

[0037] (2) Screening of mutant enzyme activity The reaction premix formulation is as follows: glycine 75 g / L, PLP 0.25 g / L, magnesium sulfate heptahydrate 19 g / L. Dissolve the above components in 0.2M potassium phosphate buffer (pH 7.5) and bring the volume to 1L for later use. 500 µL of reaction premix and 40 µL of 37% formaldehyde (corresponding to a final formaldehyde concentration of 1 M in the 500 µL reaction system) were added sequentially to a 96-well plate. The plate was shaken at 800 rpm for 4 h at 35 °C, centrifuged at 12000 rpm for 10 min, and the supernatant was derivatized with OPA (o-phthalaldehyde). The L-serine content of the product was then detected by HPLC, and the relative enzyme activity was calculated (with wild type as control). Some results are shown in Table 3.

[0038] Enzyme activity is defined as the amount of enzyme required to produce 1 µmol of L-serine per minute, which is 1 U.

[0039] HPLC detection conditions: Shimadzu high-performance liquid chromatograph, using a C18 column (4.6*250mm, 5μm), injection volume 2μL, flow rate 0.8mL / min, column temperature 30℃, UV detection wavelength 334nm, mobile phase A: sodium acetate solution; mobile phase B: pure methanol. (3) Mutant enzyme activity rescreening First, mutants with activity higher than the wild-type control as detected by HPLC in 96-well plate reactions were inoculated into 5 mL of LB medium (kanamycin, 50 μg / mL) and cultured at 37 °C for 8–10 h. Then, 1 mL of the cultured bacterial solution was added to a 250 mL shake flask containing 50 mL of TB liquid medium containing 50 μg / mL kanamycin resistance. The flask was incubated at 37 °C and 220 rpm for approximately 2.5 h until the OD600 reached 0.6. IPTG was added to a final concentration of 0.1 mM for induction, and expression was induced at 25 °C and 220 rpm for 16 h. The cells were then centrifuged at 4 °C and 4000 rpm for 10 min to collect the wet cells. The cells were washed and resuspended with PBS buffer (50 mM, pH 7.4), and the wet cell weight was measured. The cells were then stored at -20 °C.

[0040] Thaw the frozen bacteria, then add 10 mL of reaction premix and 810 μL of 37% formaldehyde (corresponding to a final formaldehyde concentration of 1 M in a 500 µL reaction system). The formaldehyde is added in batches. The reaction is carried out at 35 °C and 220 rpm with shaking for 4 h, followed by centrifugation at 12000 rpm for 10 min. The supernatant is derivatized with OPA (o-phthalaldehyde), and the L-serine content of the product is detected by HPLC. The relative enzyme activity is calculated (with wild type as control).

[0041] Table 2. Relative enzyme activities of some mutants .

[0042] L-threonine aldolase was obtained through mutation. Pp The dominant mutants of -LTA are R248K (amino acid sequence as shown in SEQ ID No. 3 (please provide)) and L290I (amino acid sequence as shown in SEQ ID No. 4 (please provide)), and the corresponding recombinant genetically engineered bacteria are: E. coli BL21 (DE3)-pET24a- Pp -LTA-R248K (abbreviated as 248K) and E. coli BL21(DE3)-pET24a- Pp -LTA-L290I (abbreviated as 290I).

[0043] MNGETSRPPALGFSSDNIAGASPEVAQALVKHSSGQAGPYGTDELTAQVKRKFCEIFERDVEVFLVPTGTAANALCLSAMTPPWGNIYCHPASHINNDECGAPEFFSNGAKLMTVDGPAAKLDIVRLRERTREKVGDVHTTQPACVSITQATEVGSIYTLDEIEAIGDVCKSSSLGLHMDGSRFANALVSLGCSPAEMTWKAGVDALSFGATKNGVLAAEAIVLFNTSLATEMSYRRKRAGHLSSKMKFLSAQIDAYLTDDLWLRNARKANAAAQRLAQGLEGLGGVEVLGGTEANILFCRLDSAMIDALLKAGFGFYHDRWGPNVVRFVTSFATTAEDVDHLLNQVRLAADRTQERLE (SEQ ID No. 3).

[0044] MNGETSRPPALGFSSDNIAGASPEVAQALVKHSSGQAGPYGTDELTAQVKRKFCEIFERDVEVFLVPTGTAANALCLSAMTPPWGNIYCHPASHINNDECGAPEFFSNGAKLMTVDGPAAKLDIVRLRERTREKVGDVHTTQPACVSITQATEVGSIYTLDEIEAIGDVCKSSSLGLHMDGSRFANALVSLGCSPAEMTWKAGVDALSFGATKNGVLAAEAIVLFNTSLATEMSYRRKRAGHLSSKMRFLSAQIDAYLTDDLWLRNARKANAAAQRLAQGLEGLGGVEVIGGTEANILFCRLDSAMIDALLKAGFGFYHDRWGPNVVRFVTSFATTAEDVDHLLNQVRLAADRTQERLE (SEQ ID No. 4).

[0045] (4) Fermentation of recombinant genetically engineered bacteria expressing the mutant 1. Wet bacterial cells The starting strain WT constructed in Example 1 and the superior mutant recombinant genetically engineered bacteria 248K and 290I screened in Example 2 were inoculated into test tubes containing 5 mL of LB liquid medium containing 50 μg / mL kanamycin resistance, and cultured overnight at 37°C and 220 rpm in a shaker. Then, 1 mL of the overnight culture was added to a 250 mL shake flask containing 50 mL of LB liquid medium containing 100 μg / mL kanamycin resistance, and cultured at 37°C and 220 rpm in a shaker for approximately 2.5 h until the OD600 reached 0.6. IPTG was added to a final concentration of 0.1 mM for induction, and expression was induced for 16 h at 25°C and 220 rpm in a shaker. After induction, the biomass (OD600) of the bacterial culture was measured first, and then the culture was transferred to a 50 mL centrifuge tube and centrifuged at 4000 rpm for 10 min at 4°C. The supernatant and whole cells (precipitate) were obtained and subjected to SDS-PAGE, as shown in the figure. Figure 2 As shown. The wet bacterial cells are stored in a refrigerator at -20°C for later use.

[0046] 2. Crude enzyme solution 1g of the wet bacterial cells from step 1 was resuspended in 20mL of PBS buffer (50 mM, pH 7.4), and sonicated at 300W for 15min with a 2s working time followed by a 3s interval. The lysed bacterial solution was centrifuged at 4000rpm for 15min at 4℃, and the supernatant was collected to obtain the crude enzyme solution. Both the lysed bacterial solution and the crude enzyme solution can be used to catalyze the reaction of formaldehyde and glycine to produce L-serine.

[0047] Example 3: Pp The -LTA mutant catalyzes the reaction of formaldehyde and glycine to produce L-serine. Reference Figure 4 The schematic diagram illustrates the principle of L-threonine aldolase mutant catalyzing the condensation reaction of formaldehyde and glycine to produce L-serine. The synthesis reaction was carried out using the crude enzyme solution of wild type / mutant prepared by the method in Example 3 as a catalyst.

[0048] The final concentration of the 10mL reaction system consisted of: 0.8g wild-type / mutant crude enzyme, 1M formaldehyde, 75g / L glycine, 0.25g / L PLP, and potassium phosphate buffer (0.2M, pH 7.5).

[0049] The reaction solution was placed at 35°C and 220 rpm. After the reaction, a sample was derivatized with OPA (o-phthalaldehyde), and the L-serine content was then determined using HPLC as described in Example 1. The results are shown in [Figure 1]. Figure 4 As shown.

[0050] like Figure 4 As shown, when the formaldehyde concentration is 1M, the wild type PpThe L-serine yield of -LTA was 30 g / L, while the L-serine yield of mutants R248K and L290I increased from 28% to 76%.

[0051] The above description is merely a preferred embodiment of the present invention and is not intended to limit the scope of the invention. Various variations can be made to the above embodiments of the present invention. All simple and equivalent changes and modifications made in accordance with the claims and description of this application fall within the protection scope of the claims of this patent. All aspects not described in detail in this invention are conventional technical content.

Claims

1. An L-threonine aldolase mutant, characterized in that: The L-threonine aldolase mutant was obtained by making a single mutation at amino acid position 248 or 290 of the amino acid sequence of the wild-type L-threonine aldolase shown in SEQ ID No.

2.

2. The L-threonine aldolase mutant as described in claim 1, characterized in that: The L-threonine aldolase mutant is obtained by replacing serine at position 248 or 290 of the amino acid sequence shown in SEQ ID No. 2 with lysine or isoleucine.

3. The gene encoding the L-threonine aldolase mutant as described in claim 1.

4. A recombinant expression vector for expressing the L-threonine aldolase mutant encoding gene as described in claim 3.

5. A method for the efficient catalytic production of L-serine using an L-threonine aldolase mutant, characterized in that: Using wet cell culture obtained by fermentation of recombinant expression transformant of L-threonine aldolase mutant or crude enzyme solution obtained by ultrasonic disruption of wet cell culture as catalyst, formaldehyde and glycine as substrate, pyridoxal phosphate and magnesium sulfate heptahydrate are added, and a buffer solution with pH 6-10 is used as the reaction medium to form a reaction system. The reaction is carried out at 30-50℃ and 200-300 rpm to obtain a reaction solution containing L-serine.

6. The method for efficiently producing L-serine using an L-threonine aldolase mutant as described in claim 5, characterized in that: The amount of catalyst added in the reaction system is 10-80 g / L based on the weight of wet bacterial cells or wet bacterial cells before ultrasonic disruption; the final concentration of formaldehyde is 0.1-1 M; the final concentration of glycine is 10-100 g / L; the final concentration of pyridoxal phosphate is 10-200 mg / L; and the final concentration of magnesium sulfate heptahydrate is 8-19 g / L.

7. The method for efficiently producing L-serine using an L-threonine aldolase mutant as described in claim 5, characterized in that: The buffer solution is a 0.2M, pH 7.5 potassium phosphate buffer.

8. The method for efficiently producing L-serine using an L-threonine aldolase mutant as described in claim 5, characterized in that: The catalyst was prepared as follows: The recombinant expression transformant of the L-threonine aldolase mutant was inoculated into a test tube containing LB liquid medium with 50 μg / mL kanamycin and cultured overnight at 37°C and 220 rpm in a shaker. The bacterial culture was inoculated at a volume concentration of 1% into TB liquid medium containing 50 μg / L kanamycin and cultured at 37°C and 220 rpm in a shaker until the OD600 reached 0.6-0.

8. 0.1 mM IPTG was added to a final concentration, and the culture was induced for expression at 25°C and 220 rpm for 12-14 h. The culture was then centrifuged at 4°C and 4000 rpm for 10 min to obtain wet cells. The wet cells were resuspended in 50 mM PBS buffer (pH 7.4) and washed. The supernatant was discarded after centrifugation at 4000 rpm for 10 min to obtain wet cells. The wet cells were then added at a concentration of 50 g / L to 50 mM PBS buffer (pH 7.4). Resuspend the enzyme in 0.4% PBS buffer, sonicate at 300W for 10 min, working for 2 seconds and then 3 seconds, centrifuge at 4000 rpm for 15 min at 4℃, collect the supernatant to obtain crude enzyme solution.

9. The method for efficiently producing L-serine using an L-threonine aldolase mutant as described in claim 5, characterized in that: The formaldehyde was added in batches and gradually. Specifically, during the reaction, a formaldehyde solution with a concentration range of 10 to 300 millimoles per liter (mM) was added to the reaction system in portions at set time intervals.

10. The method for efficiently producing L-serine using an L-threonine aldolase mutant as described in claim 5, characterized in that: The catalyst can also be a purified solution, wet bacterial cells, crude enzyme solution, or freeze-dried enzyme powder of pure enzyme solution.